TY - JOUR AU - Viteri, Santiago AU - Rosell, Rafael PY - 2017 TI - Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients JF - Translational Cancer Research; Vol 6, Supplement 3 (May 26, 2017): Translational Cancer Research Y2 - 2017 KW - N2 - In The Lancet , Jean Charles Soria and colleagues presented the results of the ASCEND-4 study: a randomized phase 3 trial comparing ceritinib against platinum doublet chemotherapy as first line treatment for non-small cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) rearrangements that included 376 patients (189 in the ceritinib arm and 187 in the chemotherapy arm) (1). UR - https://tcr.amegroups.org/article/view/13588